Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 219

1.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators..

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

2.

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.

Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC.

Neuroendocrinology. 2015;102(1-2):18-25. doi: 10.1159/000381715.

PMID:
25824001
3.

GEPNETs update: Radionuclide therapy in neuroendocrine tumors.

van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ.

Eur J Endocrinol. 2015 Jan;172(1):R1-8. doi: 10.1530/EJE-14-0488. Review.

4.

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.

Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A.

Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173.

5.

Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.

Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ.

Am J Surg. 2014 Nov;208(5):775-80. doi: 10.1016/j.amjsurg.2014.04.003.

PMID:
24997491
6.

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A.

Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113.

PMID:
24632546
7.

Recommendations for management of patients with neuroendocrine liver metastases.

Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R; Working Group on Neuroendocrine Liver Metastases..

Lancet Oncol. 2014 Jan;15(1):e8-21. doi: 10.1016/S1470-2045(13)70362-0. Review.

PMID:
24384494
8.

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.

Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L.

Gastrointest Cancer Res. 2013 May;6(3):81-5.

9.

Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage.

Henderson-Jackson EB, Nasir A, Chen DT, Nandyala P, Djeu J, Strosberg J, Kvols L, Coppola D.

Pancreas. 2013 Aug;42(6):967-70. doi: 10.1097/MPA.0b013e318293734b.

10.

A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.

Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH.

Endocr Relat Cancer. 2013 May 21;20(3):383-90. doi: 10.1530/ERC-12-0390.

11.

Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.

Saranga-Perry V, Morse B, Centeno B, Kvols L, Strosberg J.

Neuroendocrinology. 2013;97(4):318-21. doi: 10.1159/000345938.

PMID:
23296364
12.

Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.

Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK.

J Clin Oncol. 2013 Feb 1;31(4):420-5. doi: 10.1200/JCO.2012.44.5924.

PMID:
23248248
13.

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B.

Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367.

14.

Treatment of liver metastases in patients with neuroendocrine tumors.

Granberg D, de Herder W, O'Toole D, Kvols L.

Int J Hepatol. 2012;2012:790635. doi: 10.1155/2012/790635. No abstract available.

15.

Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.

Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK.

Ann Surg. 2012 Aug;256(2):321-5. doi: 10.1097/SLA.0b013e31824e6108.

PMID:
22415420
16.

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK.

Ann Oncol. 2012 Sep;23(9):2335-41. doi: 10.1093/annonc/mdr614.

17.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group..

Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X.

PMID:
22119496
18.

Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas.

Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A.

Anticancer Res. 2011 Sep;31(9):2957-62.

PMID:
21868544
19.

Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK.

J Clin Oncol. 2011 Aug 1;29(22):3044-9. doi: 10.1200/JCO.2011.35.1817.

PMID:
21709192
20.

Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors.

Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J.

J Hematol Oncol. 2011 Jun 14;4:29. doi: 10.1186/1756-8722-4-29. Review.

Items per page

Supplemental Content

Loading ...
Support Center